These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12323018)

  • 1. Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease.
    Kogen H; Toda N; Tago K; Marumoto S; Takami K; Ori M; Yamada N; Koyama K; Naruto S; Abe K; Yamazaki R; Hara T; Aoyagi A; Abe Y; Kaneko T
    Org Lett; 2002 Oct; 4(20):3359-62. PubMed ID: 12323018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter.
    Toda N; Kaneko T; Kogen H
    Chem Pharm Bull (Tokyo); 2010 Mar; 58(3):273-87. PubMed ID: 20190429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
    Rodríguez-Lavado J; Gallardo-Garrido C; Mallea M; Bustos V; Osorio R; Hödar-Salazar M; Chung H; Araya-Maturana R; Lorca M; Pessoa-Mahana CD; Mella-Raipán J; Saitz C; Jaque P; Reyes-Parada M; Iturriaga-Vásquez P; Pessoa-Mahana H
    Eur J Med Chem; 2020 Jul; 198():112368. PubMed ID: 32388114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease.
    Toda N; Tago K; Marumoto S; Takami K; Ori M; Yamada N; Koyama K; Naruto S; Abe K; Yamazaki R; Hara T; Aoyagi A; Abe Y; Kaneko T; Kogen H
    Bioorg Med Chem; 2003 May; 11(9):1935-55. PubMed ID: 12670645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease.
    Toda N; Tago K; Marumoto S; Takami K; Ori M; Yamada N; Koyama K; Naruto S; Abe K; Yamazaki R; Hara T; Aoyagi A; Abe Y; Kaneko T; Kogen H
    Bioorg Med Chem; 2003 Oct; 11(20):4389-415. PubMed ID: 13129577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
    Castro A; Martinez A
    Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
    Li RS; Wang XB; Hu XJ; Kong LY
    Bioorg Med Chem Lett; 2013 May; 23(9):2636-41. PubMed ID: 23511019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
    Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
    Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.
    Liu S; Shang R; Shi L; Zhou R; He J; Wan DC
    Chem Biol Drug Des; 2014 Aug; 84(2):169-74. PubMed ID: 24890706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives.
    Chakravarty H; Ju Y; Chen WH; Tam KY
    Drug Dev Res; 2020 Apr; 81(2):242-255. PubMed ID: 31837041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and cholinesterase inhibition assay of liquiritigenin derivatives as anti-Alzheimer's activity.
    Guan L; Peng D; Zhang L; Jia J; Jiang H
    Bioorg Med Chem Lett; 2021 Nov; 52():128306. PubMed ID: 34371131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives.
    Rampa A; Bisi A; Belluti F; Gobbi S; Valenti P; Andrisano V; Cavrini V; Cavalli A; Recanatini M
    Bioorg Med Chem; 2000 Mar; 8(3):497-506. PubMed ID: 10732965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
    Zhou LY; Zhu Y; Jiang YR; Zhao XJ; Guo D
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4180-4184. PubMed ID: 28751142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
    Catto M; Pisani L; Leonetti F; Nicolotti O; Pesce P; Stefanachi A; Cellamare S; Carotti A
    Bioorg Med Chem; 2013 Jan; 21(1):146-52. PubMed ID: 23199476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and cholinesterase inhibitory activity study of new piperidone grafted spiropyrrolidines.
    Basiri A; Abd Razik BM; Ezzat MO; Kia Y; Kumar RS; Almansour AI; Arumugam N; Murugaiyah V
    Bioorg Chem; 2017 Dec; 75():210-216. PubMed ID: 28987876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
    Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
    ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment.
    Zhu J; Wang LN; Cai R; Geng SQ; Dong YF; Liu YM
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1325-1329. PubMed ID: 30956012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors.
    Stavrakov G; Philipova I; Lukarski A; Atanasova M; Zheleva D; Zhivkova ZD; Ivanov S; Atanasova T; Konstantinov S; Doytchinova I
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32717861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease.
    Manzoor S; Gabr MT; Rasool B; Pal K; Hoda N
    Bioorg Chem; 2021 Nov; 116():105354. PubMed ID: 34562674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.